首页> 外文期刊>BMC Nephrology >Rapid reduction of high-level pre-formed donor-specific antibodies after simultaneous liver-kidney transplantation: a report of two cases
【24h】

Rapid reduction of high-level pre-formed donor-specific antibodies after simultaneous liver-kidney transplantation: a report of two cases

机译:同时肝肾移植后的高水平预形成供体特异性抗体的快速减少:两种情况的报告

获取原文
           

摘要

Kidney transplantation performed in the presence of high-titre donor-specific antibodies (DSA) may result in hyper-acute or accelerated antibody-mediated rejection and rapid allograft loss. Previous studies have shown that this risk may be mitigated with simultaneous liver-kidney transplantation (SLKT); however, the mechanisms are not well defined. Here we report the evolution of pre-formed, high-level DSAs in two highly sensitised SLKT recipients peri-operatively and describe a profound sustained depletion of all DSAs from the time of liver anastomosis with no extra desensitisation therapy required. Two patients underwent SLKT and received our centre’s standard renal transplant immunosuppression with basiliximab and methylprednisolone for induction therapy and prednisolone, mycophenolate and tacrolimus for maintenance therapy. HLA antibody samples were collected pre-operatively, and immediately post-liver and post-kidney revascularisation, and then regularly in the post-transplant period. Complement Dependant Cytotoxicity (CDC) crossmatches were also performed. Both patients were highly sensitised with a PRA over 97%. One patient had a positive B- and T-cell crossmatch pre-transplant. These positive CDC crossmatches became negative and the level of pre-formed DSAs reduced profoundly and rapidly, within 3?h post-liver revascularisation. The reduction in pre-formed DSAs, regardless of subclass, was seen immediately post-liver revascularisation, before implantation of the renal allografts. No significant reduction in non-donor specific HLA-antibodies was observed. Both patients maintained good graft function with no rejection on kidney allograft protocol biopsies performed at 10-weeks post-transplant. These cases support the protective immunoregulatory role of the liver in the setting of SLKT, with no extra desensitisation treatment given pre-operatively for these highly sensitised patients.
机译:在高滴度供体特异性抗体(DSA)存在下进行的肾移植可能导致超急性或加速抗体介导的抑制和快速同种异体移植损失。以前的研究表明,这种风险可以通过同时肝肾移植(SLKT)来减轻这种风险;但是,机制没有明确定义。在这里,我们报告了预先形成的高级别DSA的演变,在两个高度敏感的SLKT接受者中,从肝脏吻合时间内描述了所有DSA的深刻持续消耗,无需额外的脱盐疗法。两名患者接受了SLKT,并通过Basiliximab和甲基己酮酮接受了中心的标准肾移植免疫抑制,用于诱导治疗和泼尼松龙,霉酚酸盐和躯干治疗治疗。 HLA抗体样品被预操作地收集,并立即肝脏后和肾后血管体外,然后定期在移植后期进行。还进行了补体依赖性细胞毒性(CDC)交叉迁移。两位患者都以超过97%的PRA高度敏感。一名患者有阳性B-和T细胞交叉迁移预移植。这些阳性CDC交叉迁移变为阴性,并且预先形成的DSA水平较小且迅速地减少了肝脏后血型血管后的3μl。在植入肾同种异体移植物之前,在肝脏血管外,在肝脏后血管后发现,预先形成的DSA的减少。观察到非供体特异性HLA抗体的显着减少。两名患者认为良好的接枝功能,不会在移植后10周龄在10周龄在10周龄进行的肾同种异体移植协议活检的排斥反应。这些病例支持肝脏在SLKT设置中的保护性免疫调节作用,对于这些高度敏感的患者进行预先持续施用,没有额外的脱敏治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号